Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasm, Residual 1Mesothelioma 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Kidney Neoplasms 1Graft vs Host Disease 1Carcinoma, Renal Cell 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 17Paclitaxel 16Radiotherapy 10Taxes 9Cisplatin 8Radiation 7Docetaxel 7Gemcitabine 6Gefitinib 6Bevacizumab 6Erlotinib Hydrochloride 5Radiotherapy, Conformal 3Platinum 3Etoposide 31,2-diaminocyclohexaneplatinum II citrate 3methoxyamine 2Vinorelbine 2Tirapazamine 2Pemetrexed 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Disulfides 2Cetuximab 2Bortezomib 2veliparib 1vandetanib 1shark cartilage extract 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma of Lung × Pentostatin × Clear all
NCT01362790 2019-06-06

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
55 enrolled 22 charts
GastrointestinalOther solid neoplasmThoracic

Adenocarcinoma of Lung, Mesothelioma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡